A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AB-506, an HBV Capsid Inhibitor, in Healthy Caucasian and East Asian Subjects for 28 Days
Latest Information Update: 19 Nov 2019
At a glance
- Drugs AB-506 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Arbutus Biopharma
Most Recent Events
- 03 Oct 2019 Status changed from active, no longer recruiting to discontinued, according to an Arbutus Biopharma media release.
- 24 Sep 2019 Status changed from not yet recruiting to active, no longer recruiting.
- 12 Sep 2019 Recruitment completion is expected on [21-09-2019] according to [Australian New Zealand Clinical Trials Registry]